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ABSTRACT
Carcinoma-associated fibroblasts were reported to promote colorectal cancer 
(CRC) invasion by secreting motility factors and extracellular matrix processing 
enzymes. Less is known whether fibroblasts may induce CRC cancer cell motility 
by contact-dependent mechanisms. To address this question we characterized the 
interaction between fibroblasts and SW620 and HT29 colorectal cancer cells in 2D and 
3D co-culture models in vitro. Here we show that fibroblasts induce contact-dependent 
cancer cell elongation, motility and invasiveness independently of deposited matrix or 
secreted factors. These effects depend on fibroblast cell surface-associated fibroblast 
growth factor (FGF) -2. Inhibition of FGF-2 or FGF receptors (FGFRs) signaling 
abolishes these effects. FGFRs activate SRC in cancer cells and inhibition or silencing of 
SRC in cancer cells, but not in fibroblasts, prevents fibroblasts-mediated effects. Using 
an RGD-based integrin antagonist and function-blocking antibodies we demonstrate 
that cancer cell adhesion to fibroblasts requires integrin αvβ5. Taken together, these 
results demonstrate that fibroblasts induce cell-contact-dependent colorectal cancer 
cell migration and invasion under 2D and 3D conditions in vitro through fibroblast cell 
surface-associated FGF-2, FGF receptor-mediated SRC activation and αvβ5 integrin-
dependent cancer cell adhesion to fibroblasts. The FGF-2-FGFRs-SRC-αvβ5 integrin loop 
might be explored as candidate therapeutic target to block colorectal cancer invasion.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer in the world. Despite advances in treatments, 
existing therapies are of limited effectiveness once cancer 
has become invasive or metastatic [1]. Understanding the 
molecular mechanisms underlying CRC cell invasion may 
lead to the identification of patients at high risk for disease 
progression and to the discovery of novel therapeutic 
targets and strategies. During tumor progression cancer 
cells modify the surrounding normal tissue to create 
a microenvironment supporting tumor growth and 
progression [2]. The tumor microenvironment consists 
of a variety of tumor-recruited or locally activated cells, 
such as bone marrow-derived cells, immune cells and 
carcinoma-associated fibroblasts (CAF) [3]. Dynamic 
reciprocal interactions between tumor cells and their 
microenvironment contribute to tumor cell survival, 
proliferation, invasion and metastasis and are therefore 
increasingly considered as potential targets for novel 
therapeutic strategies [4].
Despite the fact that CAF are among the most 
abundant and crucial cells of the tumor microenvironment, 
these cells remains poorly defined due to their inherent 
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plasticity, heterogeneity and different origins, as well as 
the lack of single, universal specific markers and their 
pleiotropic functions [5–8]. Nevertheless, several distinct 
morphological properties and functions of CAF have been 
described and characterized. CAF are contractile cells 
commonly characterized by the expression of multiple 
activation markers, including α-smooth muscle actin 
(SMA), vimentin (VIM) or fibroblast-activated protein 
(FAP) [9, 10]. The presence of CAF is associated with 
aggressive progression and poor prognosis in several 
cancer types [11–13]. Experimental and clinical evidences 
indicate that CAF regulate a number of tumor-promoting 
functions, including angiogenesis, invasion and metastasis 
[9, 14]. The higher CAF density is generally found at 
the invasive front of the tumor [10], and several studies 
have shown that CAF promote CRC progression though 
multiple mechanisms [10, 11, 15]. Firstly, CAF produce 
soluble factors, such as hepatocyte growth factor/scatter 
factor (HGF) and platelet-derived growth factor (PDGF), 
promoting survival, proliferation and motility of cancer 
cells and stimulating the recruitment and activation of 
other cells in the tumor microenvironment, in particular 
inflammatory cells [16, 17]. Secondly, CAF induce 
angiogenesis and enhance vascular permeability through 
the secretion of vascular endothelial growth factor 
(VEGF) [18]. Thirdly, CAF promote cancer cells invasion 
by modifying extracellular matrix (ECM) through the 
deposition of matrix proteins, including tenascins [11, 19], 
and the secretion of matrix metallo-proteases (MMPs) 
resulting in altered tensile forces, gradients and release 
of bioactive fragments promoting cancer cell motility 
[11, 20]. In spite of the fact that CAF can be in contact 
with cancer cells during stroma invasion [19] only little 
is known on the putative role of direct CAF-cancer cell 
contact in promoting cancer cell motility and invasion.
Here we have addressed this question by 
characterizing the interaction between fibroblasts and 
CRC-derived cell lines SW620 and HT29 in vitro 
using 2D and 3D co-culture models. Presented results 
demonstrate that fibroblasts promote CRC cell migration 
and invasion through direct cell-cell contact involving 
fibroblast cell surface associated FGF-2 and FGF receptors 
(FGFR) - integrin αvβ5-SRC dependent signaling in 
cancer cells.
RESULTS
Fibroblasts promote SW620 and HT29 CRC cell 
elongation and motility
To monitor the effect of fibroblasts on CRC cell we 
cultured the CRC-derived cell lines SW620 and HT29 in 
the absence or presence of skin-derived fibroblasts. When 
cultured alone, SW620 and HT29 have a rather rounded 
morphology, while after 48 hours culture in the presence 
of fibroblasts they acquire an elongated morphology 
(Fig. 1A). Time lapse imaging revealed that only cancer 
cells establishing contacts with fibroblasts develop 
pseudopodia at the attachment site and progressively 
acquire an elongated morphology over time (about 70% 
of SW620 and 50% of HT29 compared to less than 
10% in the absence of fibroblasts) (Fig. 1B and 1C). 
Concomitant to elongation, cancer cells cultured with 
fibroblasts massively increased their motility, as monitored 
by tracking the distance travelled by individual cells 
(Fig. 1D).
These results demonstrate that fibroblasts induce 
colon cancer cell elongation and motility.
Cultured dermal, normal colon or colon cancer 
fibroblasts have equivalent gene expression and 
activation profiles and induce comparable cancer 
cell elongation and motility
Next we tested whether fibroblasts isolated from 
normal colon (CFB) or colon cancer (CAF) tissues 
were also able to induce cancer cell elongation and 
motility. Indeed, CFB and CAF induced SW620 and 
HT29 elongation and motility to extents comparable to 
those exerted by dermal fibroblasts (Fig. 2A-2C). The 
fact that dermal fibroblasts and CFB were able to induce 
these effects on CRC cells was unexpected, as previous 
studies demonstrated that only freshly isolated CAF, but 
not normal fibroblasts, induced cancer progression in vivo 
[21, 22].
To explain these similar properties, we hypothesized 
that fibroblasts cultured and expanded in vitro might 
acquire common functional capabilities regardless of 
their in vivo origin. To substantiate this hypothesis we 
performed gene expression profiling analyses on CFB, 
CAF and dermal fibroblasts (FB). Self-organizing heat-
maps of the top 100 differentially expressed genes revealed 
that all fibroblasts display a very similar expression profile 
(Fig. 2D). As comparison, umbilical cord endothelial 
cells (HUVEC) have a clearly different gene expression 
profile. Moreover Principal Component Analysis (PCA) 
confirmed that all tree fibroblasts populations cluster 
together and clearly segregate from HUVEC (Fig. 2E). In 
addition volcano plot analysis confirms the results (data 
not shown).
To further strengthen these observations we 
monitored transcripts profiles for fibroblasts activation 
markers typically observed in CAF [10, 15]: α-SMA, 
FAP, stroma-derived factor (SDF)-1, interleukin-6 (IL-6), 
VIM and fibroblasts specific protein (FSP)-1. Transcripts 
for all these markers were similarly expressed across all 
fibroblasts populations, thereby indicating equivalent 
activation states (Fig. 2F). FSP-1 and VIM were also 
expressed in cancer cells, consistent with previous reports 
[23, 24].
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To collect further evidence supporting the notion 
that ex vivo culture alters gene expression profile in 
fibroblasts, we performed gene expression profiling 
analyses on CAF and CFB and compared them to 
expression profiles of laser-capture micro-dissected CRC 
stroma and normal colon stroma. PCA demonstrate that 
laser micro-dissected normal stroma and reactive stroma 
have different expression profile, while cultured CAF and 
CAB have similar expression profiles (Fig. 3A). Normal 
colonic epithelial cells and cancer segregate separately. 
Self-organizing maps of genomics profiles further 
confirmed that expression profiles of cultured CAF and 
CFB were indistinguishable (Fig. 3B), while genomics 
profiles of laser-capture micro-dissected tumor stroma 
Figure 1: Fibroblasts induce cancer cell elongation and motility. A. Representative images of SW620 and HT29 cancer 
cells (red) in absence or presence of dermal fibroblasts (+FB, green). Bar graphs represent quantification of cancer cells elongation. 
B. Time course of cancer cells elongation quantification. C. Representative live images of adhesion between fibroblasts (green) and cancer 
cells (red). D. Quantification of cancer cells motility during 48 hours in presence or absence of fibroblasts. All data are represented as 
mean +/− SD.
Oncotarget14303www.impactjournals.com/oncotarget
and normal stroma showed clear differences (Fig. 3C) 
consistent with the notion that in vivo differences in gene 
expression are blunted by in vitro cell culture.
Taken together these results indicate that cultured 
dermal fibroblasts, CFB and CAF are in a similar state 
of activation and are equally effective in inducing colon 
cancer cells elongation and motility in our model. Since 
CFB and CAF have reduced proliferative capacity 
in vitro compared to dermal fibroblasts (data not shown), 
we performed most of the experiments using dermal 
fibroblasts whereas CFB and CAF were used in selected 
validation experiments.
Cancer cell elongation and migration require 
direct contact with living fibroblasts
As elongated cancer cells were closely associated 
with fibroblasts we asked the question whether direct 
contact was required or whether soluble factors or 
extracellular matrix were sufficient in mediating such 
effects. To this purpose SW620 and HT29 were exposed 
to conditioned medium from fibroblast cultures or 
fibroblast-cancer cell co-cultures. Both conditions 
were ineffective in inducing cancer cell elongation 
or motility (Fig. 4A and Supplementary Fig. 1A). 
Figure 2: Cultured dermal, colon and colon cancer associated fibroblasts induce similarly cancer cell elongation and 
motility and have equivalent gene expression and activation profiles. A. Representative images of SW620-GFP co-cultured 
with dermal fibroblasts (FB), normal colon fibroblasts (CFB) and colon cancer associated fibroblasts (CAF). B. Quantification of cancer 
cell elongation with CFB and CAF, represented as mean +/− SD. C. Quantification of SW620 motility during 48 hours culture with CFB 
and CAF, represented as mean +/− SD. D. Self-organizing heat-maps of the top 100 genes with greatest variability across all samples, 
showing similar expression profile for Colon Normal Fibroblasts (cFB_N), Colon Cancer Fibroblasts (cFB_T) and Dermal Fibroblasts 
(dFB_N), but highly different profiles compare to HUVEC (HU). E. PCA plot demonstrating that Colon Normal Fibroblasts (n), Colon 
Cancer Fibroblasts (t) and Dermal Fibroblasts (d) are similar, while they greatly diverge from HUVEC (e). F. PCR expression analysis of 
fibroblast activation markers.
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In addition, cancer cells cultured on an ECM deposited 
by fibroblasts, as demonstrated by the detection of 
fibronectin (Supplementary Fig. 2A), or on fixed 
fibroblasts, did not acquire elongation or motility 
(Fig. 4B and Supplementary Fig. 1B). Elongated 
cancer cells isolated from an established co-culture and 
re-plated in the absence of fibroblasts reverted to a round 
morphology (Fig. 4C and Supplementary Fig. 1C). 
The purity of cancer cell fraction isolated from 
co-culture with fibroblasts was over 95% (Supplementary 
Fig. 2B and 2C). Importantly cancer cell co-cultured 
with HUVECs did not result in any effect on elongation 
or migration (Fig. 4D and Supplementary Fig. 1D). 
Exposure of SW620 or HT29 to exogenous FGF-2, 
EGF and TGFβ, three cytokines known to induce cancer 
cell motility, failed to induce elongation and migration 
(Supplementary Fig. 3A and 3B).
From these experiments we concluded that 
fibroblast-induced SW620 and HT29 cell elongation 
and motility require continuous contact with living 
fibroblasts.
Fibroblasts promote contact-dependent cancer 
cell invasion
To test whether fibroblasts can also promote cancer 
cell invasion, we used 2D and 3D spheroid assays. For the 
2D assay, SW620 spheroids were cultured on a fibroblasts 
monolayer for 4 days. Fibroblasts induced SW620 cell 
scattering and migration out of the spheroids (Fig. 5A-5B). 
SW620 migrating along fibroblasts acquired an elongated 
morphology (Fig. 5C). Culturing tumor spheroids alone, 
with co-culture conditioned medium, on a gelatin substrate 
or on a HUVEC monolayer did not induce cancer cell 
invasion (Fig. 5D and Supplementary Fig. 3C), thereby 
confirming that the effect was fibroblast specific and 
contact dependent. We then tested for fibroblasts-induced 
cancer cell invasion in 3D conditions by embedding 
Figure 3: Normal and colon cancer stroma have different gene expression profiles in vivo while fibroblasts isolated 
thereof and cultured in vitro have similar profiles. A. PCA plot representing similar expression profile for in vitro cultured colon 
normal fibroblasts (F), colon cancer fibroblasts (C) and the lung fibroblasts MRC5 cell line (D). In contrast, profiles of laser-capture micro-
dissection normal stroma (S) and reactive stroma (R) segregate distinctly along component 1. Tumor cells (T) and normal colon epithelial 
cells (N) have completely different profiles compared to stromal cells. B. Self-organizing maps of cultured CAF and CFB showing very 
similar genomics profiles. Color scale shows A average. C. Self-organizing maps showing different genomics profiles of reactive stroma 
(RS) and normal stroma (S) freshly dissected by laser-capture micro-dissection.
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SW620 cells spheroids in fibroblasts-supplemented 
Matrigel. Fibroblasts migrated toward the spheroids, 
established contacts with cancer cells and induced SW620 
invasion into the surrounding matrix. SW620 spheroids 
embedded in Matrigel without fibroblasts did not develop 
invasive properties (Fig. 5E).
From these experiments we concluded that 
fibroblasts induce contact-dependent cancer cell invasion.
Figure 4: Fibroblast-induced elongation and motility of cancer cells require direct contact with living fibroblasts.  
A. Representative images of SW620-GFP cultured in the presence or absence of fibroblasts, fibroblasts and co-culture (cc) conditioned 
media. Bar graphs represent quantification of SW620 elongation and motility for 48 h. B. Representative images of SW620-GFP cultured 
on ECM deposited by fibroblasts and on a fixed fibroblast layer. Bar graphs represent quantification of SW620 cell elongation and motility 
for 48 h. C. Representative image and quantification of elongation of SW620-GFP returned to culture after separation from established  
co-culture. D. Representative images and quantification of elongation and motility of SW620-GFP cultured with HUVECs and fibroblasts 
for 48 h. All data are represented as mean +/− SD.
Oncotarget14306www.impactjournals.com/oncotarget
Cancer cell elongation, migration and invasion 
require FGFR signaling
In order to define the molecular mechanism 
involved in contact-dependent fibroblast-induced cancer 
cell elongation, migration and invasion, we applied 
pharmacological inhibitors of several known invasion-
promoting kinases (i.e. PI3K/AKT, c-MET, MAPK/ERK, 
EGFR or FGFR) to co-cultures. Of all the tested inhibitors, 
only the FGFR inhibitors PD-161570 and PD-173074 
prevented fibroblasts-induced cancer cell elongation 
Figure 5: Fibroblasts induce cancer cell invasion in 2D and 3D conditions. A. Representative images of SW620-GFP 
invasion from spheroids cultured for 4 days alone or on a fibroblast-DsRED layer (2D condition). B. Quantification of SW620 invasion 
of experiment in panel A, represented as mean +/− SD. C. Image of SW620-GFP invading the fibroblast layer out of a spheroid. 
D. Quantification of SW620-GFP spheroid invasion after 4 days under indicated conditions represented as mean +/− SD. E. Representative 
images of SW620-GFP 3D spheroids in presence or absence of fibroblasts-DsRED after 4 days. Arrows are indicating invasion areas.
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(Supplementary Fig. 4A and 4B). PD-161570 and 
PD-173074 also inhibited cancer cell migration (Fig. 6A 
and Supplementary Fig. 4C) and invasion in the 2D 
(Fig. 6B) and 3D (Fig. 6C) assays.
Exogenous soluble FGF-2 did not induce cancer 
cell elongation (Supplementary Fig. 3A and 3B) and 
FGF-2 protein was readily detected by Western blotting 
in fibroblast but not in cancer cell lysates (Fig. 6D). 
mRNA level of FGF-2 was also much higher in fibroblasts 
compared to cancer cells (Fig. 6E), however FGF-2 protein 
levels were identical in culture supernatants of fibroblasts, 
cancer cells and co-cultures (Fig. 6F). Co-culture with 
Figure 6: Cancer cell migration and invasion depends of fibroblast-cell surface associated FGF-2 and FGFR 
signaling. A. Quantification of SW620 motility cultured with fibroblasts in the absence or presence of PD-161570 and PD-173074 FGFR 
inhibitors for 48 h. B. Quantification of SW620 2D spheroid invasion cultured as indicated after 4 days. C. Representative images of 
SW620-LifeAct-mCherry 3D spheroid invasion cultured with fibroblasts-LifeAct-GFP in the absence or presence of FGFR inhibitors 
after 4 days. D. Western blotting analysis of FGF-2 protein in fibroblasts, cancer cells alone and in co-culture with (“(+FB)”) or without 
(“+FB”) cancer cell separation. E. Relative expression of FGF-2 mRNA in fibroblasts, SW620 and HT29 determined by RT-PCR. F. ELISA 
quantification of soluble FGF-2 in cell culture supernatants as indicated. All data are represented as mean +/− SD.
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cancer cells further enhanced fibroblasts FGF-2 mRNA 
expression by about 3 fold (Supplementary Fig. 4D).
Cancer cells adhesion on fibroblast requires 
fibroblast surface-associated FGF-2, FGFR 
signaling and αVβ5 integrin ligation
These observations suggested that immobilized, 
rather than soluble FGF-2 might be responsible for 
these effects. To demonstrate that FGF-2 was localized 
at the cell surface, cell surface proteins were labeled 
with biotin, isolated by avidin precipitation and 
analyzed by Western blotting for FGF-2. Indeed FGF-2, 
but not GAPDH (a typical cytoplasmic protein) 
was detected in the biotinylated membrane protein 
fraction of fibroblasts cultures (Fig. 7A). These results 
demonstrate the presence of FGF-2 at the cell surface. 
Consistent with this observation, SW620 and HT29 
adhesion on fibroblasts was strongly reduced in the 
presence of an anti-FGF-2 antibody and small molecular 
FGFR kinase inhibitors (Fig. 7B and Supplementary 
Fig. 5A). Furthermore, an αVβ3/αVβ5 integrin blocking 
cyclic RGD peptide, EMD-121974, and an anti-αVβ5 
blocking antibody, but not anti-αVβ6 or anti-β1 blocking 
antibodies, strongly reduced SW620 and HT29 adhesion 
on fibroblasts (Fig. 7C and Supplementary Fig. 5B). 
Expression of αVβ5 and αVβ6, but not αVβ3 on cancer 
cells, was demonstrated by flow cytometry analysis 
and was not altered by co-culture with cancer cells 
(Supplementary Fig. 5C).
Figure 7: Fibroblasts cell surface-associated FGF-2, FGFR and αvβ5 integrin are required for SW620 cell adhesion 
to fibroblasts. A. Western blot of FGF-2 from normal cell lysate and from the extracted membrane proteins fraction. B. Adhesion of 
SW620 on a fibroblast layer in presence or absence of FGFR inhibitors and a FGF-2 specific blocking antibody. C. Adhesion of SW620 on 
fibroblasts in presence of EMD-121974, and specific integrin blocking antibodies as indicated. All data are represented as mean +/− SD.
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From these experiments we concluded that SW620 
and HT29 CRC cell adhesion to fibroblasts depends on 
fibroblasts cell surface associated FGF-2, FGFR signaling 
and αVβ5 integrin ligation.
Fibroblasts-induced cancer cells adhesion, 
elongation, migration and invasion require 
SRC activation in cancer cells
Next we looked for an intracellular signaling 
pathway mediating FGF-2/FGFR-induced cancer cell 
elongation, migration and invasion. As inhibition of 
PI3K/AKT, MAPK/ERK, ROCK and FAK did not 
prevent these effects (Supplementary Fig. 4A), we 
focused on SRC, a kinase downstream of FGFR and 
integrins known to modulate cell adhesion, migration 
and invasion [25, 26]. Basal levels of membrane-
associated phospho-SRC were observed in SW620 
and HT29 cultured alone and more frequently in 
elongated cancer cells, in particular at sites of contact 
with fibroblasts. Nuclear phospho-SRC was observed 
in cancer cells in contact with fibroblasts and in 
fibroblasts themselves (Fig. 8A and Supplementary 
Fig. 6A). Inhibition of FGFR kinase activity fully or 
partially inhibited SRC phosphorylation (Supplementary 
Fig. 6B). Inhibition of SRC activity with PP-2 or CGP-
77675 (Supplementary Fig. 6C) effectively inhibited 
SW620 and HT29 adhesion on fibroblasts (Fig. 8B and 
Supplementary Fig. 6D), fibroblasts-induced SW620 
and HT29 elongation and motility during co-cultures 
(Fig. 8C-8E and Supplementary Fig. 6E and 6F). 
The related inactive compound PP-3 was ineffective 
to induce any effect. SRC inhibition also prevented 
scattering and invasion of cancer cells in the 2D and 
3D spheroid models (Fig. 8F and Fig. 9). Importantly, 
under these experimental conditions, SRC and 
FGFR inhibitors were not cytotoxic (Supplementary 
Fig. 6G).
The use of pharmacological inhibitors in these 
experiments has two main limitations: inhibitors are 
not fully specific and may affect other SRC family 
members (i.e. Yes, Fyn, Fgr, Lck or Hck) and also target 
SRC in fibroblasts. To circumvent these limitations we 
silenced SRC through lentiviral-mediated expression 
of SRC-specific shRNA in cancer cells or in fibroblasts 
(Supplementary Fig. 7A). SW620 and HT29 cells with 
silenced SRC failed to elongate and migrate in the 
presence of fibroblasts (Supplementary Fig. 7B-7D). 
In contrast, fibroblasts with silenced SRC expression 
were still able to induce cancer cell elongation 
(Supplementary Fig. 7E and 7F).
From these experiments we concluded that 
fibroblast-induced cancer cell elongation, motility and 
invasion depend on SRC activation in cancer cells.
DISCUSSION
CAF promote cancer invasion and metastasis 
through the combined promotion of cancer cell growth, 
survival and motility, induction of angiogenesis and 
ECM modification [10, 15 , 19]. These effects are largely 
considered mediated by released factors (i.e. cytokines, 
chemokines, angiogenic factors and matrix proteases). 
Considering the close physical proximity of cancer cells 
and CAF at CRC invading fronts [9], it appears reasonable 
that direct CAF-cancer cell contact may also play a role. 
To date, however, the role of direct CAF contact in CRC 
cell invasion and the putative involved mechanisms remain 
largely elusive. Here we addressed this question by using 
in vitro 2D and 3D co-cultures systems SW620 and HT29 
CRC cells and cultured dermal, normal colon and colon 
cancer fibroblasts. We found that fibroblasts induce cancer 
cell motility and invasion in a cell-contact dependent 
manner and we provide a mechanism: Fibroblasts surface 
associated FGF-2 activates FGFR on cancer cells, which in 
turn activates SRC. Activated SRC induces integrin αvβ5-
dependent tumor cell adhesion to fibroblasts and tumor 
cell motility (Fig. 10). In 2D models, cancer cells migrate 
along fibroblasts while in the 3D models fibroblasts “pull” 
cancer cells to initiate and guide migration into the gel.
The relevance of our results relies on the following 
implications. Firstly, they demonstrate the functional 
importance of direct fibroblast-cancer cell contact. In vivo 
this may be especially important under conditions of 
migration along precise paths, such as matrix fibers 
[27], or when cancer cells have not yet acquired full 
invasive capacities, for instance during invasion in the 
absence of EMT [28]. To corroborate this hypothesis 
additional experiments using several cancer cell lines with 
different degree of malignancy and in vivo experiments 
are necessary. Secondly, they provide a new role for 
fibroblasts cell surface-associated FGF-2. The role of 
FGF-2 in cancer progression is well recognized [29, 30]. 
While it is well known that FGF can associate to the cell 
surface through its high affinity for glycosaminoglycans 
[31], the biological significance of cell surface FGF has 
not been well characterized. Rather, its biological activities 
have been attributed to the soluble and matrix-associated 
fraction [29]. Our observations suggest that FGF-2 may 
contribute to distinct phases of cell invasion: cell surface 
associated FGF-2 may initiate migration of poorly 
invasive cells requiring additional cell-derived stimuli, 
while matrix-associated FGF-2 might enhance invasion 
of already invasive cells. The exact process of FGF-2 
presentation at the cell surface leading to these effects 
remains unknown at this point and its elucidation will 
require additional work. Thirdly, we identify FGFR, SRC 
and αvβ5 as the molecules mediating cancer cell adhesion 
on fibroblasts, migration and invasion. To our surprise, 
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αvβ6, an integrin up-regulated in CRC (and present 
on CRC cells) and contributing to CRC invasiveness 
through the activation of TGF-β and production of MMPs 
[32], was not involved in this effect. How FGFR, SRC 
and αvβ5 interact in this context, in particular whether 
activated FGFR associate with αvβ5 integrin, remains 
still unknown. As β5 integrin and FGFR1 are reported 
to promote CRC progression [33, 34], we performed 
co-immunoprecipitation experiments to test whether 
these receptors may associate upon FGF-2 presentation. 
However, we could not demonstrate co-precipitation of β5 
integrin and FGFR1 under mild detergent conditions and 
complex stabilization by surface protein-protein cross-
linking (Supplementary Fig. 8). Although preliminary, 
these results suggest that either FGFR1 is not the 
receptor of interest for this effect, among the FGFR 
family members, or that indeed FGFR1 and αvβ5 do not 
associate. Additional experiments are necessary to clarify 
this point. The exact role of SRC signaling and nuclear 
translocation remains also open. Preliminary observations 
indicate that SRC is not regulating αvβ5 activity through 
direct phosphorylation of the β5 cytoplasmic domain 
(data not shown). A further important open question 
concerns the αvβ5 ligand on the fibroblast surface. As 
FGF-2 was reported to bind to αvβ3 [35], we tested 
whether SW620 and HT29 cells adhered to immobilized 
FGF in a αvβ5-dependent manner. While cancer cells 
adhered to immobilized FGF-2 this adhesion was not 
integrin dependent (data not shown). We also tested the 
potential role of heparin, which is a necessary binding-
partner for FGF-2 in order to stabilize receptor binding 
and dimerization. However, results suggest that heparin 
is not playing a detectable role in promoting/perturbing 
cancer cell adhesion to fibroblasts (data not shown). 
A role of fibroblast surface fibronectin, as a possible 
αvβ5 ligand for cancer cell adhesion, was also excluded 
Figure 8: SRC in cancer cells mediate elongation, migration and invasion induced by fibroblasts. A. Representative 
images of SW620 SRC activation (green) in the presence or absence of fibroblasts, stained with DAPI (blue) and Phalloïdin (red). 
B. Adhesion of SW620 on fibroblasts in presence or not of PP-3 (neg. ctrl), PP-2 and CGP-77675 SRC inhibitors. C. Representatives images 
of SW620-GFP cultured with PP-3, PP-2 and CGP-77675 in the presence of fibroblasts for 48 h. D. Quantification of SW620 elongation 
with or without SRC inhibitors. E. Quantification of SW620 motility with or without SRC inhibitors for 48 hours. F. Quantification of 
SW620 2D spheroid invasion as indicated after 4 days. All data are represented as mean +/− SD.
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Figure 9: SRC in cancer cells mediate invasion induced by fibroblasts. Representative images of SW620-mCherry 3D spheroid 
invasion after 4 days with fibroblasts-GFP cultured with PP-3, PP-2 and CGP-77675 SRC inhibitors as indicated.
Figure 10: Schematic representation of the proposed mechanism of fibroblast mediated contact-dependent cancer cell 
migration. Fibroblasts surface associated FGF-2 activates FGFR on cancer cells, which in turn activates SRC. Activated SRC induces 
integrin αvβ5-dependent tumor cell adhesion to fibroblasts and tumor cell motility.
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using anti-fibronectin-adhesion blocking antibodies (data 
not shown). Further, N-cadherin, which was reported to 
promote cancer cell invasion and metastasis in association 
with FGFR1 [36] and fibroblasts, was also excluded as 
not expressed in these cancer cells (data not shown). 
We are now considering additional candidate ligands. 
Fourthly, as inhibitors of FGFs, FGFRs, SRC and αv 
integrins are in preclinical development or already 
available for clinical testing [37–40], these results provide 
a rationale for in vivo preclinical testing and focusing 
on their clinical assessment in invasive CRC. To assess 
the clinical relevance of these in vitro observations, we 
performed preliminary immunohistochemical stainings 
for FGF-2 and FGFR1 on human colorectal cancer 
samples. Representative results, shown in Supplementary 
Fig. 9, confirm the presence of FGF-2 in both cancer 
cells and stromal cells. FGFR1 staining is present on 
more differentiate areas of the cancer, but lost in more 
transformed, and invasive regions. This is consistent with 
concurrent observations suggesting that FGFR1 is not 
the major receptor involved in this process. Membrane 
localization on fibroblasts cannot be confirmed in these 
stainings. Fifthly, they raise a fundamental question on the 
role of fibroblasts in cancer cell invasion: which cues do 
cancer cells gain from adhering on fibroblasts to initiate 
elongation and migration, that they cannot acquire through 
fibroblasts-released factors and deposited matrix? Initial 
experiments addressing this question indicate that cell 
contact induces important changes in gene expression in 
both fibroblasts and cancer cells.
A corollary of this study is the observation 
that fibroblasts cultured and expanded in vitro have 
similar gene expression profiles and activation markers 
independently on the in vivo origin, including for those 
originally from the tumor stroma. These observations, in 
combination with the results from laser micro-dissected 
stroma, suggest that comparative studies of CAF vs. 
normal fibroblasts are best performed using freshly 
isolated, non-cultured, cells.
In conclusion, we show that fibroblasts induce cell-
contact-dependent CRC cell migration and invasion under 
2D and 3D conditions in vitro through surface associated 
FGF-2, FGFR-mediated activation of the SRC in cancer 
cells and αvβ5-mediated adhesion. Further characterization 
of this effect may reveal novel aspects on the cancer 
invasion-promoting role of fibroblasts.
MATERIALS AND METHODS
Cell culture
The human colorectal carcinoma cell lines SW620 
and HT29, and HEK-293T cells were purchased from 
ATCC (LGC Standards). CAF, dermal and colon 
fibroblasts and Human Umbilical Vein Endothelial 
Cells (HUVEC) were obtained from human samples. 
SW620 were cultured in RPMI GlutaMAX™, HT29, 
all fibroblasts and HEK-293T in DMEM GlutaMAX™, 
all supplemented with 10% FCS, 100 U/ml Penicillin 
and 100 μg/ml Streptomycin. HUVECs were cultured as 
described previously [41]. All cell culture reagents were 
purchased from Life Technologies.
For co-culture experiments, fibroblasts and colon 
cancer cells were grown for 48 hours at a 1:1 ratio in 
DMEM GlutaMAX™. Conditioned media were harvested 
after 72 hours of culture and filter 0.45 μM before use. 
Coatings were performed over-night using porcine Gelatin 
0.5% (Sigma), Poly-L-Lysine 0.1% (Life Technologies), 
human Fibronectin 0.1% (Sigma) and 1% Rat Tail 
Collagen Type I (BD Bioscience) in PBS. TGF-β (Sigma) 
was used at 20 ng/ml, EGF and FGF-2 (Cell Signaling) 
at 100 pg/ml. Cell counting and viability determination 
was performed by trypan blue exclusion using Neubauer 
Counting Chamber.
To produce conditioned matrix, fibroblasts were 
grown to confluence for 3 days, and then detached 
over-night at 4°C using 20 mM EDTA (Sigma), 10 μg/ml 
Leupeptin (Sigma), 1 mM PMSF (Sigma) and 10 μg/ml 
Soybean (Sigma). For fibroblast layer fixation, 4% PFA 
(Electron Microscopy Sciences) was applied for 2 minutes 
followed by washing with PBS.
Inhibitors were used at the indicated concentrations 
and blocking antibodies at 10 μg/ml, all added to the 
serum free medium and incubated with cancer cells and 
fibroblasts for 48 hours.
Inhibitors of signaling
Y-27632 (Sigma), PP-3 and PP-2 (ABCAM) were 
used at 10 μM, Ly-294002 (Sigma) and PD-98059 (Enzo 
Life Sciences Inc.) at 20 μM, CGP-77675 (Sigma) at 
5 μM, SU-11274 (Sigma) at 2 μM, Wortmannin (Sigma) 
at 0.1 μM, AG-1478 (Merck Millipore) at 200 nM, 
PF-562271 (Pfizer), PD-173074 (Tocris), EMD-121974 
(Medkoo Biosciences), PF-573228 and PD-161570 
(Sigma) at 1 μM.
Antibodies
The following antibodies against human were used 
for Western blotting and immunoprecipitation technic: 
Anti-GAPDH (Sigma), anti-phospho-SRC Tyr416 and 
anti-SRC (Cell Signaling), anti-FGF-2 (Thermo Fisher 
Scientific Inc.), anti-FGFR1 and anti-β5 (Cell Signaling), 
all at 1/1000 dilution. Secondary antibodies used were: 
anti-rabbit-HRP and anti-mouse-HRP (Dako), both at 
1/1000 dilution.
For FACS analysis, anti-αv-PE and anti-β5 
(Biolegend), anti-β3-PE and anti-αvβ3-PE (BD 
Biosciences), anti-β6 (clone IC8C3, Dr. D. Sheppard, 
Oncotarget14313www.impactjournals.com/oncotarget
UCSF, San Francisco) were used at 1/100 dilution. 
Anti-αvβ5 (clone P5H9, R&D Systems) and anti-αvβ6 
(clone 10D5, Merck Millipore) were used for FACS at 
1/50 dilution, and for function blocking experiments 
at 10 μg/ml, as well as anti-FGF-2 (R&D Systems) and 
anti-β1 (clone Lia1/2, Beckman). Dead Cell Apoptosis Kit 
for PI-Annexin V staining was from Life technologies.
Anti-phospho-SRC Tyr416 (Cell Signaling), anti-
FGFR1 (Cell Signaling), anti-Phalloïdin-AlexaFluor 546 
(Invitrogen), anti-FGF-2 (Thermo Fisher Scientific Inc.), 
as well as anti-αSMA (Sigma), anti-pan-Cytokeratin 
(Dako) and DAPI ProLong Gold mounting medium 
(Invitrogen) were used for immunofluorescent staining 
and immunohistochemistry.
Co-culture separation
Cancer cells were separated from fibroblasts using 
MACS® separation technique, following manufacturer’s 
instructions. MS columns and anti- human Fibroblast 
micro-beads were used. All reagents were from Miltenyi 
Biotec.
Isolation of fibroblasts and HUVEC
Dermal fibroblasts were isolated from human 
neonatal foreskin. Excised skin samples were was placed 
into Ca2+, Mg2+-free Hank’s balanced salt solution (Life 
Technologies) with 100 U/ml Penicillin-Streptomycin 
(Life Technologies) and 5 μg/ml Gentamicin (Sigma). 
After removal of subcutaneous fat, skin samples were 
incubated 2 hours at 37°C with 2–4 ml of collagenase 
type I 1 mg/ml (Roche). Cell suspension was harvested 
on ice, quenched by adding DMEM and filtered 70 μM. 
2’000’000 cells per dish were plated with DMEM. The 
medium was replaced twice a week and cells maintained 
up to 80% confluence. Dermal fibroblasts were used up to 
15 passages.
Colon fibroblasts and CAF were isolated according 
to the protocol by Orimo et al. [21]. Tissue sections, 
obtained following colectomy for colon cancer, of about 
1 cm3 were collected in 15 ml DMEM, transported on ice 
and washed about 5 times with DMEM, before being cut 
into small pieces, washed again and incubated for 12 h 
at 37°C with agitation in 2–4 ml DMEM containing 
collagenase type I 1 mg/ml and 120 units hyaluronidase 
(Sigma). The dissociated tissues were incubated without 
shaking for 5 minutes at room temperature, followed by 
the separation of stromal cell-enriched supernatant to 
a new tube. The stromal fraction was centrifuged and 
cells were cultured on tissue culture plates in DMEM for 
15–20 cell passages.
HUVEC were isolated as previously described [42] 
from fresh umbilical cords dissociation.
Protocols for collection and use of human samples 
were approved by the Ethic committees of Cantons Vaud, 
Berne and Ticino, Switzerland.
Spheroids assay
Cancer cells spheroids were prepared as previously 
described [43], using the hanging drop technic in a 
Terazaki plate with 500 cells per well in 20 μl medium for 
72 h. 3D spheroids assay were performed according to the 
3D-On-Top method [44]. 7 mg/ml Matrigel growth factors 
reduced (Corning) was used as matrix, mixed or not with 
75’000 fibroblasts/ml. For 2D spheroids assay, cancer cell 
spheroids were placed on top of a confluent fibroblasts 
layer or on coated wells.
Vectors and infections
LifeAct lentiviral vectors in GFP and mCherry 
were kindly provided by Dr. Olivier Pertz. pSD44 lenti-
vector expressing GFP and DsRED were pRRLSIN.cPPT.
PGK/GFP.WPRE lentiviral vector under the control of 
the phospho glycerate kinase promoter. SRC pLKO.1 
shRNA were from Thermo Fisher Scientific Inc. and used 
following manufacturer’s instructions.
Lentiviral particles were generated in HEK-293T 
cells by transducing the vector of interest with pMD2G 
(pSD11) and pMDLgpRRE (pSD16) plasmids using 
calcium phosphate transfection [45], followed, depending 
of the vector used, by an antibiotic-based selection of the 
infected cells.
Western blotting
Cells were lysed using RIPA lysis buffer (Cell 
Signaling) supplemented with protease Cocktail inhibitor 
(Sigma), 2 mM PMSF, 2 mM BGE (Sigma) and 0.2 mM 
Orthovanadate (Sigma) on ice and re-suspended in SDS 
buffer containing 10% Glycerol, 5% β-mercatoethanol, 
60 mM Tris-Cl, trace of bromophenol blue and 2% SDS, 
all from Sigma. SDS-PAGE, blotting, and detection were 
performed as previously described [46].
Cell Surface Protein Isolation Kit (Pierce) was used 
for isolation of membrane proteins fraction following 
manufacturer’s instructions.
Co-Immunoprecipitation
Cells were lysed using RIPA non-denaturant lysis 
buffer (Cell Signaling) supplemented with protease 
Cocktail inhibitor, 2 mM PMSF, 2 mM BGE and 0.2 mM 
Orthovanadate on ice. After sonication and centrifugation 
the supernatant was incubated for 12 hours at 4°C under 
agitation with primary antibody at 1/50 dilution. The mix 
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was then incubate for 30 minutes at 4°C with protein A 
magnetic beads (Cell Signaling), followed by beads 
isolation using magnetic separation rack (Cell Signaling). 
Samples was heated for 5 minutes at 95°C, mixed with 
SDS buffer and processed by SDS-PAGE and Western 
blotting.
For protein cross-linking experiments, cells 
were treated for 30 minutes at room temperature with 
2 mM DSP (Thermo Fisher Scientific Inc.) followed by 
15 minutes quenching using 1 M Tris pH 7.5. Cells were 
lysed and processed as above.
ELISA
For FGF-2 quantification, ELISA assays (Biolegend) 
was performed following manufacturer’s instructions. 
For fibronectin detection, fibroblasts were removed from 
cell culture plates as previously described, wells were 
blocked using 5% BSA and incubated with anti-fibronectin 
antibody (Sigma), followed by a goat-anti-mouse-HRP 
antibody and a chromogenic substrate (Biolegend). 
Absorption was measured at 630 nm and normalized 
comparing fibronectin coated-wells.
Flow cytometry
Annexin V/PI staining was performed following 
manufacturer’s instructions (Life Technologies). Integrin 
staining were performed using directly labeled anti-
integrin primary antibodies 1:100 dilution 30 minutes 
on ice or unlabeled primary antibodies followed by 
30 minutes secondary antibody anti-rabbit or mouse-PE 
(BD Bioscience) incubation on ice (1:100 dilution). PBS 
with 3% FCS and 5 mM EDTA was used as buffer. BD 
FACSCalibur (Becton Dickinson) instrument was used 
to perform experiments and FlowJo 9.7.4 (Treestar Inc.) 
software was used to analyze all data.
Adhesion assay
8’000 fibroblasts were cultured in a 96-wells plate 
to reach confluence. 15’000 GFP-cancer cells were added 
on fibroblasts layer and incubated in serum free medium 
for 3 hours. Non-adherent cells were removed using ice 
cold PBS and adherent cells were observed and quantified 
using fluorescence microscopy.
Immunostaining
Cells were grown on a glass chamber-slide 
previously coated with Poly-L-lysine followed 
by 10 minutes fixation with 4% PFA, 5 minutes 
permeabilisation with 0.1% Triton X-100 (Sigma) in PBS 
and blocking for 30 minutes with PBS containing 0.05% 
BSA, 5% Donkey serum (Fitzgerald) and 0.1% Triton 
X-100. Primary antibody was incubated over-night at 4°C 
at 1/100 dilution. Secondary and third antibodies were 
incubated for 1 hour at room temperature in blocking 
at 1/100 dilution. DAPI staining was included in the 
mounting medium.
For immunohistochemistry, paraffin embedded 
organ cuts were pre-treated 30 minutes with Citrate 
(Leica) for FGF-2 and FGFR1 stainings, or 15 minutes 
in Enzyme (Leica) for Cytokeratin staining. Primary 
antibodies were incubated for 30 minutes at the following 
dilutions: FGF-2, 1:25; FGFR1, 1:50; Cytokeratin, 1:200; 
αSMA, 1:8000. Slide stainings were performed on Leica 
BOND RX system following manufacturer’s instructions.
RT-PCR
mRNA was extracted using RNeasy Mini kit 
(Qiagen) and total RNA was retro-transcribed using 
Superscript following manufacturer’s instructions 
(Promega AG). cDNA was subjected to PCR 
amplifications using the following primer pairs 
(Eurofins MWG Operon) at the indicated hybridization 
temperatures. Real-time qPCR was performed using 
the StepOne SYBR System (Life Technologies). 
















Gene expression analysis by microarray 
hybridization
Laser capture micro-dissections were performed 
as described in the paper of Farmer et al. [47]. RNA 
extraction, micro-array and data analysis were performed 
as described in the paper of Christensen et al. [48]. 
The complete data set is publicly available at GEO (http://
www.ncbi.nlm.nih.gov/geo/) through the accession 
number GSE30292 and GSE23583.
Robust multi-array averaging (RMA) and quantile 
normalization were used to quantify gene expression, 
for non-supervised hierarchical clustering Pearson’s 
correlation and average linkage clustering, respectively, 
were used for similarity measurement and clustering using 
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R (R 2.12.0, Bioconductor 2.7). Principle component 
analysis was performed using R 3.1.
Gene expression analysis by RNASeq
All fibroblasts and HUVEC cells were grown at 
the same time in triplicate from independent patients at 
passage 6. Total RNA was extracted using the total RNA 
extraction Nucleospin II kit (Machery-Nagel). The quality 
and quantity of all RNA samples were examined by 
Agilent 2100 Bioanalyzer (Agilent Biotechnologies) and 
NanoDrop (Witec AG).
RNA-seq libraries were prepared using 15 ng of 
total RNA and the Ovation Nugen RNA-Seq System 
v2 kit (Nugen). 100 ng of the ds-cDNAs obtained were 
fragmented to 350 pb using Covaris S2 (Covaris). The 
Illumina TruSeq nano reagents (Illumina) were used 
to generate the final libraries. Cluster generation was 
performed with the resulting libraries using the Illumina 
HiSeq PE Cluster Kit v4 reagents and sequenced on the 
Illumina HiSeq 2500 using HiSeq SBS Kit v4 reagents. 
Sequencing data were processed using the Illumina 
Pipeline Software version 1.82.
Purity-filtered reads were adapters and quality 
trimmed with Cutadapt (v.1.3) and filtered for low 
complexity with seq_crumbs (v.0.1.8). Reads were 
aligned against Homo sapiens.GRCh38.76 genome using 
STAR (v.2.4.0f1) [49]. The number of read counts per 
gene locus was summarized with htseq-count (v.0.6.1) 
[50] using Homo sapiens.GRCh38.76 gene annotation. 
Quality of the RNA-seq data alignment was assessed 
using RSeQC (v.2.3.7) [51]. Reads were also aligned 
to the Homo sapiens.GRCh38.76 transcriptome using 
STAR and the estimation of the isoforms abundance was 
computed using RSEM (v.1.2.16) [52]. RSEM counts 
were used for further analysis. Principle component 
analysis was performed using log2 transformed RSEM 
counts (R 3.1). Heatmaps were generated using package 
gplots in R 3.1. The complete data set is publicly 
available at GEO through the accession number 
GSE67945.
Imaging and data analysis
For co-culture experiments images were taken 
every hour at different magnifications with an inverted 
fluorescence microscope (Leica AF6000). Cancer cell 
elongation was quantified manually by scoring individual 
cells using Image J “Cell Counter” plugin on taken images 
at 48 h co-culture. Elongated cell were defined as single 
cell with a minimal length-width rapport of 2:1, as well as 
at least one sharp-ending extremity. Cancer cells motility 
was quantified based on single cell track follow on 24 h 
microscope movies using Image J “Manual Tracking” and 
“Chemotaxis Tool” plugins.
Imaging of 2D and 3D spheroids assay were 
performed with 5× and 40× objectives with Leica 
AF6000 inverted fluorescence microscope. Invasion was 
quantified using Photoshop CS6 (Adobe) by calculating 
the invaded area on the 4 days image, normalized on initial 
spheroid size.
Western Blot images were quantified for protein 
level using Image J “Gel Analyze Tool” plugin.
For immunostaining images were taken using a 
DeltaVision Elite Microscope (GE Healthcare) with 63× 
and 100× objectives, followed by deconvolution treatment.
For immunohistochemistry images, slides were 
scanned using a NanoZoomer 2.0 HT (Hamamatsu) and 
images were extracted using NDP.view2 analysis software 
(Hamamatsu).
Statistical analysis
Each experiment was repeated independently a 
minimum of 3 times in triplicate conditions. Acquired 
data were analyzed using Prism Software (GraphPad). 
Statistical comparisons were performed by un-paired 
two-tailed Student’s t test or by two-way ANOVA with 
Bonferroni post-test. Results were considered to be 
significantly from p < 0.05. In the figures the various 
p values thresholds are presented as follow: ≤0.05 = *, 
≤0.01 = **, ≤0.001 = ***, ≤0.0001 = ****.
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